共 5 条
- [1] Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : 2793 - 2806
- [5] Pneumocystis Pneumonia in Patients Treated With Rituximab [J]. CHEST, 2013, 144 (01) : 258 - 265